\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n6 November 2020
\n \n \n \nAspirin will be investigated in the world\u2019s largest clinical trial of treatments for patients hospitalised with COVID-19. The RECOVERY trial is taking place in 176 hospital sites across the UK, and has so far recruited over 16,000 patients. Patients with COVID-19 are at higher risk of blood clots forming in their blood vessels. Platelets seem to be hyperreactive in COVID-19 and may be involved in the clotting complications. As an antiplatelet agent, aspirin may reduce the risk of blood clots in patients with COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n27 October 2020
\n \n \n \nIn January 2020, ISARIC launched an international initiative for standardised COVID-19 clinical data collection. To date, ISARIC has collected data from over 118,000 individuals from 648 sites across 52 countries. To maximise the impact of this global collaboration, ISARIC has partnered with IDDO, which has over a decade\u2019s worth of experience in collecting and standardising disparate data from various diseases and areas around the world. Together, ISARIC and IDDO are developing systems that include working with those who collect the data to generate collaborative analysis, and building data governance systems that allow data to be shared more widely.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n23 October 2020
\n \n \n \nOxford is world-famous for research excellence and home to some of the most talented people from across the globe. To showcase our global research, the University launched a Global Research Map, highlighting areas of research we are conducting overseas.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n9 October 2020
\n \n \n \nAfrica accounts for 17% of the global population but only 3.5% of the reported global COVID-19 deaths. In many African countries, transmission has been higher but severity and mortality much lower than originally predicted based on experience in China and Europe. Kevin Marsh and Moses Alobo argue that Africa\u2019s much younger population explains a very large part of the apparent difference. Some of the remaining gap is probably due to under reporting of events but there are a number of other plausible explanations, ranging from climatic differences, pre-existing immunity, genetic factors to behavioural differences.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n21 September 2020
\n \n \n \nA series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n21 September 2020
\n \n \n \nProfessor Trudie Lang is Highly Commended for 'Enabling Research in Low-Income Settings During Disease Outbreaks: Implementing, Learning and Preparing' in the Building Capacity category of the University Vice-Chancellor Innovation Awards 2020.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n15 September 2020
\n \n \n \nRECOVERY, one of the world\u2019s largest efforts to find effective COVID-19 treatments, will evaluate the impact of Regeneron\u2019s REGN-COV2 investigational antibody cocktail on mortality, hospital stays, and the need for ventilation in the UK. RECOVERY aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n15 September 2020
\n \n \n \nWe are delighted to announce that Professor Paul Newton has won the Helen-Clark-JoPPP Award for Pharmaceutical Policy and Practice Research. This award is based on the scientific merit of his work, as well as its impact on patients, decisions makers, and on governments. It recognizes the talents of exceptional researchers who are making a significant contribution to the field of pharmaceutical policy and practice.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n10 September 2020
\n \n \n \nResearch Malaria Microscopy Standards (ReMMS) applicable to malaria clinical research studies have been published in Malaria Journal. The paper describes the rationale for proposed standards to prepare, stain and examine blood films for malaria parasites.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n9 September 2020
\n \n \n \nISARIC has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study. The patient survey has been designed to assess long-term health and psychosocial consequences of COVID-19 at serial intervals for up to three to five years, depending on resources.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n5 August 2020
\n \n \n \nBlog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n5 August 2020
\n \n \n \nOver the past few weeks, the UK government has gradually eased national lockdown measures. As the economy reopens, the number of contacts an individual has with other people inevitably increases. Since then, there has been an increase in COVID-19 cases, as well as spikes in transmission in certain areas. In response, rather than locking down the whole country again, the government has brought in local lockdowns in affected areas. Lakshmi Manoharan, Medical Epidemiologist at ERGO tells us how to make local lockdowns a success.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n21 July 2020
\n \n \n \nIDDO and MORU released its Medicine Quality Scientific Literature Surveyor. The surveyor delivers summaries of published scientific reports on the quality of the classes of essential medicines listed below, across regions and over time. We hope it will help medicine regulators, scientists, health professionals, purchasers and officials fill critical information gaps.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n21 July 2020
\n \n \n \nA team of scientists at Oxford University\u2019s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published in The Lancet indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n17 July 2020
\n \n \n \nThe higher education sector globally has been disrupted by the COVID-19 pandemic. Academics have been discussing various aspects of the disruptions in a series of webinars organised by the University of Cape Town. One area of particular interest is how the pandemic could affect international research collaborations. The Conversation Africa\u2019s Nontobeko Mtshali asked Professor Kevin Marsh and two other panellists to share their views.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n15 July 2020
\n \n \n \nThe global research community asks for the right research in the right places for COVID-19. The Global Health Network, the African Academy of Sciences and UK Collaborative on Development Research release a report in Nature that calls for the use of research evidence on the optimal implementation of public health interventions for COVID-19 in varied global settings.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n14 July 2020
\n \n \n \nThe UK should change its COVID-19 strategy to try to eliminate COVID-19 even without a vaccine rather than simply managing the disease. New Zealand has effectively managed to eliminate the virus, but can states with much larger, denser populations that have experienced much bigger outbreaks hope to do the same? Or is it more realistic to accept that the disease is likely to continue to circulate at some level and plan for that? Lakshmi Manoharan, Medical Epidemiologist with ERGO, tells us we should focus on reducing the amount of community transmission first before allowing economic and social activity to resume as normal.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n9 July 2020
\n \n \n \nA major UK research study into the long-term health impacts of COVID-19 on hospitalised patients, involving researchers from the University of Liverpool, has been launched.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n6 July 2020
\n \n \n \nOxford University\u2019s LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n\n \n\n\n
\n \n\n \n3 July 2020
\n \n \n \nThe European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford. The Ebola vaccine has already been deployed in the North Kivu region of the Democratic Republic of the Congo (DRC), following recommendation from the WHO\u2019s Strategic Advisory Group of Experts (SAGE), and in Rwanda \u2013 following conditional approval in 2019 under an \u2018exceptional emergency\u2019 \u2013 as part of outbreak containment efforts in the region.
\n \n\n \n \n